Sloan Lecturer Bill Fischer writes for Forbes about the disruption possibilities in new and alternative dairy products, non-prescription hearing augmentation devices and electric vehicle technology. “Disruption is, at least in these three industries, alive and well and posing a considerable threat to formerly successful, incumbent market-leaders,” writes Fischer.
David Lucchino ’06 and Prof. Robert Langer have co-founded Frequency Therapeutics, a biotechnology company focused on developing a new approach to restoring hearing from the most common form of hearing loss, reports Jack Kelly for Forbes. “FX-322 is designed to treat the underlying cause of SNHL (sensorineural hearing loss) by regenerating sensory hair cells through activation of progenitor cells already present in the cochlea,” writes Kelly.
Boston Globe reporter Robert Weisman writes about how a new startup is using technology developed in part by Prof. Robert Langer to try to reverse hearing loss. The company is applying Langer’s research to “regenerate sensory hair cells in the inner ear to treat the noise-induced hearing loss that affects an estimated 48 million Americans and millions more worldwide.”
MIT researchers have developed a drug that could reverse hearing loss by regenerating hair cells in the ear, writes Thomas Tamblyn for The Huffington Post. Hearing loss affects about 45 million Americans and “repairing or regrowing those hair cells would be a major breakthrough,” explains Tamblyn.
By regenerating hair cells in the inner ear that detect and transmit noise to the brain, researchers from MIT and other institutions believe they can help people with hearing loss, writes Jamie Ducharme for Boston Magazine. This method of regenerating cells “holds promise for a vast array of medical issues,” explains Ducharme.